Incyte frontMIND Phase 3 study backs tafasitamab filing in first-line DLBCL

Incyte

Incyte

INCY

0.00
  • Incyte flagged Phase 3 frontMIND results for tafasitamab with lenalidomide with R-CHOP in previously untreated diffuse large B-cell lymphoma, scheduled for presentation at European Hematology Association Congress on June 13, 2026.
  • Data are positioned to support US, EU regulatory filings, with study readout described as favorable for expanding tafasitamab into first-line use.
  • Phase 1/2 updates for mutant calreticulin antibody INCA033989, due June 13, were described as showing a tolerable safety profile with meaningful clinical and molecular responses, supporting progression into Phase 3 trials in myeloproliferative neoplasms.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260512298467) on May 12, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.